Abstract:BackgroundTetrastigma hemsleyanum (T. hemsleyanum) is widely used as an adjuvant drug for tumor therapy but its antitumor therapeutic targets and molecular mechanisms have remained unclear. The prediction and analysis of natural products has previously used only network pharmacology methods to identify potential target proteins from public databases. In this study, we use comprehensive bioinformatics analysis and experimental verification to determine the antitumor mechanism of T. hemsleyanum.MethodsNetwork pharmacology analysis was used to predict the potential in vivo target proteins of T. hemsleyanum. The expression matrix and clinical data to perform an analysis of hub genes were collected from the TCGA and GTEx databases, specifically the analysis of expression, prognosis, tumor immune cell infiltration analysis, immune checkpoint genes, microsatellite instability, tumor mutational burden, tumor neoantigen, and immune microenvironment, which identify the roles and biological functions of the hub genes in pan-cancer. Finally, gene set enrichment analysis was used to verify the biological processes and signaling pathways involved in the pan-cancer expression profile.ResultsWe found 124 potential in vivo target proteins of T. hemsleyanum through network pharmacological analysis, and five hub genes (AKR1C1, MET, PTK2, PIK3R1, and CDK6) were then screened by protein–protein interaction (PPI) network analysis and molecular complex detection analysis (MCODE). Experimental intervention with an aqueous extract of T. hemsleyanum verified that these hub genes are the target proteins involved in the regulation of T. hemsleyanum in cells. A pan-cancer analysis then confirmed that CDK6 and MET are potential targets upon which T. hemsleyanum may exert antitumor action, especially in ACC, CESC, LGG, and PAAD. The CDK6 protein targeted by T. hemsleyanum is also involved in the immune and mutation process of pan-cancer, especially in the regulation of immune cell infiltration, immune checkpoint gene expression, microsatellite instability, tumor mutation burdens, and tumor neoantigens. Together, these analyses show that T. hemsleyanum affects tumor immune regulation and genomic stability. Finally, a gene set enrichment analysis confirmed that T. hemsleyanum regulates the cell cycle checkpoint.ConclusionsWe found that T. hemsleyanum can behave as an antitumor agent by acting as a potential cell cycle checkpoint inhibitor in CDK6-driven tumors, such as ACC, CESC, LGG, and PAAD, and that it acts as a tyrosine kinase receptor inhibitor that inhibits the expression of the proto-oncogene MET. Combined with an analysis of immune and mutation correlations in pan-cancer, we determined that T. hemsleyanum may function biologically as an immune regulator and interfere with the stability of the tumor genome, which is worthy of further study.

Cucurbitane Triterpenoid Entities Derived from Hemsleya Penxianensis Triggered Glioma Cell Apoptosis Via ER Stress and MAPK Signalling Cross-Talk.

Cytotoxic And Apoptosis-Inducing Activity Of Triterpene Glycosides From Holothuria Scabra And Cucumaria Frondosa Against Hepg2 Cells

New Cucurbitane-Type Triterpenoid Glucosides from the Tubers of Hemsleya Amabilis with Anti-Tumor Activity

Five New Cucurbitane-Type Triterpenoid Glycosides from the Rhizomes of Hemsleya penxianensis with Cytotoxic Activities.

Five New Cucurbitane Triterpenoids with Cytotoxic Activity from Hemsleya Jinfushanensis

Cytotoxic cucurbitane triterpenoids isolated from the rhizomes of Hemsleya amabilis

ChemInform Abstract: Three New Cucurbitane Triterpenoids from Hemsleya penxianensis and Their Cytotoxic Activities.

Bioactive Triterpenoid Saponins and Phenolic Compounds Against Glioma Cells

Novel drimane-type sesquiterpenoids and nucleosides from the<i> Helicoma</i><i> septoconstrictum</i> suppress the growth of ovarian cancer cells

Novel drimane-type sesquiterpenoids and nucleosides from the Helicoma septoconstrictum suppress the growth of ovarian cancer cells

In Vitro and in Vivo Antitumor Activity of Cucurbitacin C, a Novel Natural Product from Cucumber

New Cycloartane Triterpenes from the Aerial Parts of Cimicifuga Heracleifolia

Cyclin-Dependent Kinase 6 Identified As the Target Protein in the Antitumor Activity of Tetrastigma Hemsleyanum

Molecular mechanisms of Tetrastigma hemsleyanum Diels&Gilg against lung squamous cell carcinoma: From computational biology and experimental validation

Triterpenoids from Liquidambar Fructus induced cell apoptosis via a PI3K-AKT related signal pathway in SMMC7721 cancer cells

In Vitro Effects on Proliferation, Telomerase Activity and Apoptosis of an Eremophilanoid Sesquiterpene from Senecio Oldhamianus Maxim in Cultured Human Tumor Cell Lines.

Unique Anti-Glioblastoma Activities of Hypericin Are at the Crossroad of Biochemical and Epigenetic Events and Culminate in Tumor Cell Differentiation

A novel monocarbonyl analogue of curcumin, (1E,4E)-1,5-bis(2,3-dimethoxyphenyl)penta-1,4-dien-3-one, induced cancer cell H460 apoptosis via activation of endoplasmic reticulum stress signaling pathway.

Design, synthesis and antitumor activity of triterpenoid pyrazine derivatives from 23-hydroxybetulinic acid.

Cassane diterpenoid derivative induces apoptosis in IDH1 mutant glioma cells through the inhibition of glutaminase in vitro and in vivo

A Novel Hydroxamic Acid-Based Curcumin Derivative As Potent Histone Deacetylase Inhibitor for the Treatment of Glioblastoma.